InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors

6 May, 2020

Please click here to read more

NEWS

6 May, 2020

InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors

25 March, 2020

InteRNA steunt de campagne Innovaties in Oncologie van @Mediaplanet. Leer meer over verschillende innovaties in oncologie zoals immuuntherapieën van thought leaders, zoals Ton Schumacher online of in de New Scientist (24 maart 2020)

31 October, 2019

InteRNA presents data on potential of lead oncology development candidate INT-1B3 in immuno-oncology at the SelectBIO Immuno-Oncology Europe 2019 meeting

31 October, 2019

InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting

15 May, 2019

InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy

1-5 6-10 11-15 16-20 21-25 26-30 31-35 36-40 41-42